Kornimate/medical-research-clean huggingface dataset:
3d-printed aerosolized medication delivery assist device in patients with chronic respiratory diseases

Conditions: Chronic Pulmonary Disease

Summary: the purpose of this study is to investigate the auxiliary benefits of three-dimensional printed activating assistive devices for soft-mist inhaler on patients' utilization habit.

background： the most common treatment for chronic respiratory diseases is inhalation therapy. however, inhalation therapy requires not only correct operating skills, but also exemplary and sustained adherence from the patient. soft-mist inhaler does not require hand-mouth coordination or minimum inhalation flow rate, and the aerosol release time is longer, which can effectively deliver more medication to the respiratory tract. if the patient is unable to operate the soft-mist inhaler correctly due to abnormal finger joints or weakened hand muscles, it may affect the effectiveness of inhalation. study design： this is a one-year, single-centre, prospective randomized controlled, crossover trial. methods： this study will be conducted in the chest medicine education room on the 2nd floor of fu jen catholic university hospital. a total of 60 participants will be recruited and randomly assigned into two groups: the control group and the experimental group. data collection will be conducted after one month of intervention, followed by a crossover trial. data will be collected again after the second month of intervention, and statistical analysis will be performed. effect： this study expect that three-dimensional printed activating assistive devices for soft-mist inhaler will enhance the satisfaction and convenience of elderly patients with chronic respiratory diseases who use soft-mist inhaler, thereby increasing their medication adherence.

Eligibility criteria:
inclusion criteria: * age 45-80 years * patients diagnosed with chronic respiratory diseases requiring the use of smi medication by a physician * signed informed consent form exclusion criteria: * not a first-time user of smi medication * requires assistance from others (primary caregiver or nurse) for the operation of smi medication * refusal to participate in the trial

Keywords: soft mist inhaler device error hand strength finger muscle power coordination
irinotecan, 5-fluorouracil, and leucovorin in colorectal carcinoma

Conditions: Colorectal Carcinoma

Summary: this study will examine an investigational (experimental) agent tetrathiomolybdate (tm) combined with the chemotherapy drugs irinotecan, 5-fluorouracil (5-fu) and leucovorin (lv). this study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatment of metastatic colorectal cancer. this is a pilot clinical trial which will be studying the reactions of the patient's body and tumor to the experimental treatment described above. the purpose of this study is to find out what kind of side effects this experimental treatment causes and see how often these side effects occur.


Eligibility criteria:
inclusion criteria: * patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis. * patients may have received adjuvant chemotherapy and/or one regimen of chemotherapy for metastatic disease. patients must not have been previously treated with the combination of irinotecan/5-fu/lv. * patients must be past their 18th birthday at the time of enrollment. * patients must have a performance status of 0-2 at the time of registration. * patients must have a life expectancy of \> 3 months. * if patients have undergone recent surgery, they must have fully recovered from the effects of that surgery prior to enrollment. * patients must have a pretreatment leukocyte count \> 3,000/l, absolute neutrophil count \>1500/l, hemoglobin \>8 mg/dl, and platelet count of \> 150,000/l within 2 weeks of enrollment. * patients must have adequate renal function, as documented by a serum creatinine \< 2.0 mg/dl, and have adequate hepatic function, as documented by a serum bilirubin \< 1.1 mg/dl within 2 weeks of enrollment. exclusion criteria: * patients must not have active infection. * patients must have no serious medical or psychiatric illness, other than that treated by this study, which would limit the ability of the patient to receive protocol therapy or give informed consent. * patients must not have a history of active malignancy, other than that treated by this study, within the 12 months preceding enrollment. * pregnant or lactating women may not participate. women of reproductive age must undergo a serum pregnancy test within 14 days of enrollment. men and women of reproductive potential must use an effective contraceptive method during the study. * there must be no plans for the patient to receive concomitant antineoplastic therapy while on this protocol. all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
interest of oxygenated hypothermic perfusion (pho) in preservation of hepatic grafts from expanded criteria donors

Conditions: Hepatocellular Injury

Summary: interest of oxygenated hypothermic perfusion in preservation of hepatic grafts from expanded criteria donors.

the excellent results of liver transplantation (lt) have led to a significant increase in the number of patients awaiting transplantation. at the same time, the number of grafts remains stable. to extend the donor pool, the use of extended criteria donor (ecd) donors graft increased each year despite the fact that these graft are known to be more vulnerable to ischemia-reperfusion injuries induced by cold storage preservation (cs). their use is therefore associated with a greater risk of postoperative dysfunction of the graft. this risk can be reduced by improving preservation quality. the preservation by hypothermic oxygenated perfusion (hope) consists of keeping the graft in hypothermia (4 to 12 °c) on an machine perfusion (mp) using a specific solution, saturated with oxygen. in kidney transplantation, the use of mp has been shown to improve graft function as well as graft survival, especially for ecd grafts. in liver transplantation, experimental studies on animal models have demonstrated the superiority of hope over cs regarding graft function and survival. these results have been confirmed in humans on small retrospective series. as hope is an expensive procedure, obtaining evidence of its effectiveness could result in a reimbursement of the additional cost.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * candidates for a first orthotopic liver transplantation, without transplantation of another associated organ (kidney, pancreas, heart, lung, intestine) * with cirrhosis whatever its etiology and gravity * with or without hepatocarcinoma * having given free, informed and written consent * lt made from a whole graft, harvested from a brain-dead donor with ecd criteria, defined as the presence of at least one of the following criteria: * age\> 65 years * bmi\> 30 kg / m2 * duration of hospitalization in intensive care unit\> 7 days * natremia\> 155 mmol / l * ast\> 150 iu / ml * alt\> 170 iu / ml * occurrence of cardiac arrest before harvesting * macrovacuolar steatosis\> 30% on liver histology exclusion criteria: * history of organ transplantation * transplantation in emergency * transplantation from a living donor, a reduced graft or a graft from a deceased donor by cardiac arrest (dcd) * major persons subject to legal protection (safeguard of justice, guardianship), persons deprived of their liberty

Keywords: liver transplantation hypothermic machine liver perfusion extended criteria liver grafts
topical anesthesia for closed pkp vs retrobulbar anesthesia for open-sky pkp

Conditions: Corneal Opacity; Keratitis, Herpetic; Corneal Ulcer; Corneal Dystrophies, Hereditary

Summary: penetrating keratoplasty (pkp) is an open-sky surgery that fundamentally has not changed for more than 100 years. because conventional pkp is associated with the potential for the development of devastating complications such as expulsive suprachoroidal hemorrhage and endophthalmitis, we modified the technique to one that is a closed surgery under topical anesthesia with the anterior chamber maintained to achieve favorable results. topical anesthesia is an attractive alternative to traditional injection local anesthesia since the potentially serious complications associated with retrobulbar and peribulbar anesthesia can be avoided. the closed pkp procedure with the stable anterior chamber essentially changes the open nature of conventional pkp. the advantages, i.e., decreased surgical risks, postoperative complications, and surgical difficulties, make pkp viable in most complicated cases.


Eligibility criteria:
inclusion criteria: * active bacterial keratitis, for which ulceration progressed despite maximum antibacterial medication; * refractory fungal keratitis that did not respond to antifungal agents; * nonactive hsk, for which corneal opacities with or without new vessels involved the optical zone; * ocular acid burn and thermal burn with partial limbal deficiency (50% or less) that, after more than half a year of preoperative treatment, showed reepithelialization and less than 2 quadrants limbal neovascularization. exclusion criteria: * patients with keratolimbal allograft transplantation, total limbal stem cell deficiency secondary to ocular burns, and other ocular diseases (ie, amblyopia, age-related cataract, glaucoma, macular edema, and mac ular degeneration) were excluded.
video games therapy on balance and cognitive functions in mild to moderate impaired multiple sclerosis patients.

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is often characterized by the presence of balance and cognitive impairments. cognitive functions play a key role in balance control. simultaneously performing cognitive tasks decreases walking and balance ability (dual-task cost). rehabilitative treatment of patients with ms does not have to consider separately the motor and cognitive aspects. video-game therapy (vgt) is a novel tool that allows a multimodal training approach. vgt typically provides augmented feedback during training that can contribute to learning motor skills. the main objective of this exploratory study will be to test the effects of a commercially available vgt on balance and cognitive function in ambulatory ms patients compared to a standardized balance platform training (bpt). secondary, we will explore the effects of vgt and bpt on other domains that are usually impaired in ms population and that can be improved by motor rehabilitation, such as psychological well-being, fatigue and quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of ms (primary or secondary progressive, relapsing-remitting), without relapses in the preceding 3 months * mild to moderate balance impairments with increased fall risk, defined as tug \> 8.4s * disability rate definited by kurtzke expanded disability status scale (edss) score from 4 to 5.5, exclusion criteria: * other conditions that may affect motor function * impaired cognitive functioning (mini mental status examination score less than 24) * visual impairments (daltonism and visual acuity deficit) * medical conditions that might interfere with the ability to complete the study protocol safely. a group of healthy subjects matched for age and sex will be involved for a comparison on the instrumental data (force platforms).

Keywords: multiple sclerosis video game therapy balance cognitive functions dual tasking
a machine learning approach to identify patients with resected non-small-cell lung cancer with high risk of relapse

Conditions: Non-small Cell Lung Cancer Stage IIIA

Summary: early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. however, considering stage ia-iiia non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. there are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.

this study will use data from an already available cohort of patients enrolled in the resting study (a project funded by transcan in 2018) as a training set and data from a new concurrent cohort as validation set.

Eligibility criteria:
inclusion criteria: * patient with an early stage of non small cell lung cancer * indication of surgical resection * patient able to understand and give his consent * patient affiliated to the health insurance exclusion criteria: * patient with another cancer in the last 5 years * patient with an allergy to the contrast medium * patient under legal protection

Keywords: machine-learning resected early stage non-small cell lung cancer
the effect of rebox current in pain management

Conditions: Electric Stimulation Therapy

Summary: this post-marketing monocentric double-blind sham controlled crossover study will assess the efficacy of rebox electrotherapy in the treatment of pain. totally 72 patients will be treated with both real and sham rebox device in a crossover design with a 1:1 ratio over a 6-week period. the degree of pain intensity reduction after the real rebox stimulation will be evaluated in comparison with the sham stimulation. moreover, differences in multidimensional aspects of pain will be compared between the real and sham stimulation.


Eligibility criteria:
inclusion criteria: * patient with pain based on the following diagnoses: * myofascial musculoskeletal pain * vertebrogenic algic syndrome in the cervical, thoracic and lumbosacral regions * sacroileitis with sacroiliac joint block * cervicocranialgia * frozen shoulder syndrome * arthrosis * epicondylitis * pain in tendons, ligaments and other enthesopathies * postoperative pain * post-traumatic pain * postherpetic neuralgia * duration of pain (de novo or exacerbation of chronic pain) prior to study inclusion ranges from 2 weeks to 3 months * the average pain intensity in a given period of 2 weeks to 3 months prior to study inclusion must be nrs (numerical rating scale) \>3 * the patient may be concurrently treated with analgesics and may be undergoing manual physiotherapy (rehabilitation) exclusion criteria: * age \<18 years * local contraindications: * impaired skin integrity at the site of application (open wound, skin ulcer, burns), note: the area around the postoperative scar is not an exclusion criterion * acute inflammation of the skin or subcutaneous tissue at the application site * deep vein thrombosis (diagnosed or suspected) * general contraindications: * implanted electrical device (pacemaker, implantable cardioverter-defibrillator, deep brain stimulator, cochlear implant, etc.) * pregnancy * epilepsy * malignant cancer (diagnosed or suspected) * acute potentially life-threatening conditions * concomitant other physical therapy (electrotherapy, magnetotherapy, laser therapy, ultrasound therapy, mechanotherapy, etc.) * the rebox device was administered to the subject for any indication in the last 12 months prior to the study inclusion date * a recent change in analgesic medication (i.e., new agent or change in agent dose less than 1 week prior to the first stimulation session) or a planned change in analgesic medication during the course of the study (change in agent, change in dose), note: modification of analgesic medication during the study is possible but must be recorded * ongoing acute infection, surgery or trauma during the study * concurrent subject participation in another clinical study * subject is unable to sign informed consent

Keywords: rebox therapy electrotherapy pain treatment rebox currents
tenofovir to prevent hbv reactivation

Conditions: Hepatitis B; Lymphoma; Non-Hodgkin

Summary: the purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of hepatitis b infection, in patients who are receiving rituximab-based chemotherapy for non-hodgkin's lymphoma or cll/sll. the rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. diagnosis of non-hodgkin's lymphoma to be treated with rituximab-based chemotherapy 3. hbsag negative, anti-hbc positive exclusion criteria: 1. current therapy with known activity against hbv 2. screening alt \> 10 x uln 3. screening alt \>2 and \ 2000 iu/ml (indicates active hbv infection despite hbsag negative and require antiviral therapy) 4. life expectancy \< 3 months 5. hbsag positive 6. hiv co-infection 7. active hcv co-infection (hcv rna positive) 8. creatinine clearance \<50 ml/min 9. intolerance to tenofovir 10. women of child-bearing potential unwilling to take contraception during the study period

Keywords: non-hodgkin lymphoma hepatitis b tenofovir viread
whipple protein study

Conditions: Pancreatic Cancer; Malnutrition

Summary: study investigators aim to assess the effect of providing high-protein nutritional supplementation before and after surgery

pancreaticoduodenectomy (pd) is a complex and morbid operation that is associated with many potential complications. many people undergoing pd are malnourished due to their underlying medical condition or difficulties eating in the face of abdominal pain or obstruction from pancreatic disease. this study aims to assess the effect of high-protein dietary supplementation in improving perioperative nutrition and decreasing complications. we will randomize pd patients to an experimental arm in which they take a nutritional, high-protein supplement for 2 weeks before and after surgery, or to a control arm, where they will take a standard postoperative diet without supplementation. outcomes and nutritional parameters will be examined after they complete the supplements.

Eligibility criteria:
inclusion criteria: * patients undergoing pancreaticoduodenectomy * patients aged 18 years and older * patients able to provide written informed consent * patients able to understand and comply with study guidelines * patients able to tolerate oral intake * patients who are malnourished or at risk of malnutrition as defined by a score less than 12 on the mini-nutritional assessment exclusion criteria: * patients with a milk protein allergy * patients with a vegan diet * patients dependent on artificial enteral feeding * patients with end-stage renal disease undergoing dialysis * patients who are pregnant * patients with ongoing eating disorder or condition precluding oral intake * patients who are scheduled for pancreaticoduodenectomy but are unable to receive this surgery

Keywords: pancreaticoduodenectomy surgery nutrition protein
tacks versus glue for mesh fixation in laparoscopic ventral hernia repair treating defects between 2 and 5 cm width

Conditions: Ventral Hernia

Summary: in laparoscopic ventral hernia repair, an abundance of methods has been developed to fix the mesh to the abdominal wall, including sutures (non-absorbable or absorbable), staples (non-absorbable or absorbable), clips, tacks (non-absorbable or absorbable) and (fibrin and synthetic) glues. which fixation technique is superior, is still under evaluation. there is clearly a need for larger trials to obtain confident results on the safety and performance of glue mesh fixation and tack mesh fixation in lvhr. the hypothesis of this prospective, randomized controlled study is that post-operative pain at 4 to 6 weeks after mesh fixation with glue (liquiband® fix 8™) will not differ compared to treatment with absorbable tacks during lvhr. a total of 510 patients will be recruited for this trial. this study will assess: pain, hernia recurrence, safety, procedural characteristics, technical success, analgesic intake, period to return to normal activity and quality of life.


Eligibility criteria:
inclusion criteria: 1. patient with ventral hernia (primary or incisional) with a defect size between 2 and 5 cm and eligible for laparoscopic repair. 2. patients with asa grade i to iii. 3. patient is at least 18 years old. 4. patient must sign and date the informed consent form prior to treatment. exclusion criteria: 1. patient with a recurrence of a previously treated ventral hernia repaired with mesh. recurrences are only allowed to be included after former primary (suture) repair or retromuscular/onlay mesh repair. 2. patient is treated by open surgery. 3. patient has more than one defect. treatment of swiss-cheese defects (multiple small defects) is allowed if all defects can be treated with one mesh. total width cannot exceed 5 cm. 4. patient with a complex hernia, likely not eligible for laparoscopic repair. complexity is determined by the investigator (adhesions, small bowel resection, etc). 5. patient with a life expectancy of less than 2 years. 6. patient is suspected of being unable to comply with the study protocol. 7. patient with severe chronic obstructive pulmonary disease. 8. patient with asa iv or v. 9. patient is pregnant. 10. patient needs acute surgery. 11. patient is scheduled for surgery within 6 weeks after the index-procedure. 12. patient has fibromyalgia. 13. patient with depression as shown in patient medical record. 14. patient is enrolled in another study.